Following 11 months of groundwork and planning, construction activities at Andhra Pradesh MedTech Zone (AMTZ), the 270-acre state-of-the-art iconic park dedicated to medical device manufacturing, has been initiated.
Considered to be one of the most ambitious projects for achieving self reliance in domestically manufactured medical devices under the ‘Make in India’ initiative, AMTZ will house several capital intensive scientific facilities like Gamma Irradiation, EMI/EMC and Electric Safety Testing, Biomaterials Testing, 3-D Design and Printing Labs in close proximity for mutual benefit of over 200 manufacturing units.
A host of other common commercial facilities like Expo Hall, Convention Centre, Warehouse, etc, within the park will provide a holistic ecosystem for growth of the medical device manufacturing industry in India.
The foundation stone for AMTZ was laid on August 19, 2016, by Chief Minister of Andhra Pradesh Chandra Babu Naidu. The contracts for all the scientific facilities have already been signed with the respective service providers. The first model factory is expected to be ready by October 15 this year.
AMTZ on July 8 also signed a Memorandum of Understanding (MoU) with One97 Communications Limited, which owns and operates the Paytm online platform and the Paytm app.
The MoU with Paytm will enable medical device manufacturing companies to do cashless transactions related to scientific tests and works, trading, payments for general and social services in the AMTZ zone.
Meanwhile, the Kalam Institute of Health Technology (KIHT), India’s first institute dedicated to medical technology located at Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam, has received official approval for 100 per cent financial support from the Department of Biotechnology, Government of India.
KIHT approval comes after the launch of ‘National Biopharma Mission’ – an industry-academia collaboration for accelerating discovery research to early development for biopharmaceuticals.
The National Biopharma Mission includes an investment of $125 million from the Government of India and an equal contribution as a loan from the World Bank. It is anticipated to be a game changer for the Indian biopharmaceutical and medical devices industry.